Pretransplant Comorbidities Maintain Their Impact on Allogeneic Stem Cell Transplantation Outcome 5 Years Posttransplant: A Retrospective Study in a Single German Institution

Table 1

Patient characteristics.

Characteristic	𝑁 (%)
Male/female	136/109 (56/44)
Age
<31	40 (16.3)
31–40	48 (19.6)
41–50	74 (30.2)
51–60	56 (22.8)
61–70	27 (11)
Diagnoses
AML	98 (40.2)
ALL	45 (18.3)
MDS/sAML	13 (5.3)
CML	19 (7.7)
CLL	15 (6.1)
NHL	18 (7.3)
HD	18 (7.3)
MM	8 (3.3)
SAA/FA	7 (2.8)
MPN	4 (1.6)
Conditioning regimen
BuCy	44 (18)
Cyc/TBI	27 (11)
TBI/VP16	9 (3.7)
FLAMSA/TBI	42 (17.1)
FLU/MEL140	23 (9.4)
FLU/TREO	16 (6.5)
FLAMSA no TBI	6 (2.4)
TBI 2 Gy	7 (2.9)
TBI 2 Gy/FLU	28 (11.4)
Other	43 (17.6)
Donor type
Related	87 (35.5)
Unrelated	158 (64.5)
Cell source
PBMC	230 (94)
Marrow	12 (4.9)
N.a.	3 (1.1)
Prior HSCT
No prior HSCT	223 (91)
Prior autologous PBSC	22 (9)

AML: acute myeloid leukaemia; ALL: acute lymphocytic leukaemia; MDS/sAML: myelodysplastic syndrome/secondary AML; CML: chronic myeloid leukaemia; CLL: chronic lymphocytic leukaemia; NHL: non-Hodgkin’s lymphoma; HD: Hodgkin’s lymphoma; MM: multiple myeloma; SAA/FA: severe aplastic anemia/fanconi anemia; MPN: myeloproliferative neoplasm; Bu: busulfan, Cy: cyclophosphamide, TBI: total body irradiation, VP16: etoposide, FLAMSA: fludarabine, Ara-C and Amsacrine, Mel: melphalan, Flu: fludarabine, Treo: treosulfan, PBMC: peripheral blood mononuclear cells; HSCT: hematopoietic stem cell transplantation.